Bristol-Myers Squibb Company has announced plans to acquire privately-held Amira Pharmaceuticals Inc of San Diego, California, paying $325 million upfront, in order to expand its portfolio into potential treatments for fibrotic diseases.
The Roche group is raising its outlook for core earnings per share in 2011 despite results for the first half of the year showing that sales, expressed in local currencies, were flat. The company expects that improvements in productivity, however, will enable it to deliver a per-share earnings increase of 10% for the year. In April, it forecast an increase in the high single-digit range.
Actelion Ltd reported a decline in revenue and a loss for the first six months of 2011 as the result of a damages award and a 12% decline in the Swiss franc value of dollar sales over the period.
The US Food and Drug Administration has approved Brilinta (ticagrelor), an oral antiplatelet medicine, to reduce the rate of cardiovascular death and heart attack in adult patients with acute coronary syndrome. The developer is AstraZeneca Plc.
A panel of the US Food and Drug and Administration voted narrowly not to recommend the approval of a first-in-class therapy developed by Bristol-Myers Squibb Company and Astra-Zeneca Plc for diabetes.
Consort Medical Plc, a London Stock-Exchange listed medical device company, is leading a consortium of institutional investors who are committing up to £16.9 million over three years to a UK company with a point-of-care diagnostics platform.
The specialist UK healthcare company, BTG Plc, has reported progress in the development and commercialisation of its own and partnered programmes, including recent UK approval of its antidote for digoxin overdose.
Novartis’s diversified healthcare portfolio underpinned group sales and profit in the 2011 second quarter with significant contributions made by sales of generic medicines, consumer health products and recently-acquired Alcon Inc.
Pfizer Ltd has withdrawn an application from the European Medicines Agency to extend the indication of its eye medicine, Macugen (pegaptanib sodium) to include the treatment of visual impairment due to diabetic macular oedema, the EMA said.
The Roche group has agreed to pay €130 million upfront to acquire 100% of a Heidelberg-based company which is developing in vitro diagnostics for the early detection and diagnosis of cervical cancer. The company is Mtm Laboratories AG.